Hanmi Pharm Co., Ltd. (128940) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hanmi Pharm Co., Ltd. (128940:KRX), powered by AI.

Current Price
₩446,500
P/E Ratio
33.7
Market Cap
5.7T
Sector
Healthcare
What is the Hanmi Pharm Co., Ltd. stock price forecast?

Hanmi Pharm Co., Ltd. is currently trading at ₩446,500. View real-time AI analysis on Alpha Lenz.

What is Hanmi Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Hanmi Pharm Co., Ltd. on Alpha Lenz.

What is Hanmi Pharm Co., Ltd.'s P/E ratio?

Hanmi Pharm Co., Ltd.'s P/E ratio is 33.7.

Hanmi Pharm Co., Ltd.

KRX · 128940
₩446,500+21,000(+4.94%)Market closedKRX regular session 09:00–15:30 KST
Ask about Hanmi Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Hanmi Pharm Co., Ltd. trades at a P/E of 33.7 (premium valuation) with solid ROE of 14.5%.

Ask for details

Company Overview

Hanmi Pharm Co., Ltd. is a prominent pharmaceutical company known for its innovative approach to drug development and manufacturing in South Korea. Its core function centers around researching and producing a wide array of pharmaceuticals, including innovative therapies and generics, aiming to treat a multitude of health conditions. Hanmi Pharm focuses on several therapeutic areas such as oncology, diabetes, and cardiovascular diseases, driving advancements with its cutting-edge proprietary technologies. The company is renowned for its robust R&D initiatives, evidenced by numerous patents and significant investments into creating biopharmaceuticals that cater to global health needs. In the financial market, Hanmi Pharm represents a staple in the healthcare sector, reflecting the dynamic nature of medical innovation and healthcare demand. With its headquarters strategically located in South Korea, the company not only impacts local pharmaceutical landscapes but also positions itself as a key player in the global market through strategic partnerships and international collaborations. Hanmi Pharm Co., Ltd. plays a crucial role in advancing medical treatments, contributing significantly to the pharmaceutical industry's growth and innovation.

CEO박재현
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees2,270

Company Statistics

FY 2025

Profile

₩5,720,107,481,500Market Cap
₩1,547,531,098,760Revenue
12.81MShares Out
2,270Employees

Margins

57.15%Gross
24.11%EBITDA
16.66%Operating
13.79%Pre-Tax
12.09%Net

Valuation

33.74P/E
4.58P/B
3.70EV/Sales
16.67EV/EBITDA
59.26P/FCF

Growth (CAGR)

5.14%Rev 3Yr
7.54%Rev 5Yr
17.70%Op Inc 3Yr
39.40%Op Inc 5Yr
22.60%Net Inc 3Yr
61.02%Net Inc 5Yr

Returns

9.00%ROA
14.53%ROE
11.08%ROIC

Financial Health

₩108,273,819,490Cash & Cash Equivalents
₩606,470,638,620Net Debt
50.23%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Hanmi Pharm Co., Ltd. (ticker: 128940) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,270 employees. Market cap is $5.7T.

The current price is ₩446,500 with a P/E ratio of 33.74x and P/B of 4.58x.

ROE is 14.53% and operating margin is 16.66%. Annual revenue is $1.5T.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Hanmi Pharm Co., Ltd. (128940) Stock Forecast 2026 ₩446,500 — Price, Financials & Analyst Targets | Alpha Lenz